Expert Interviews

Experts in bladder cancer discuss when it’s appropriate to use avelumab maintenance therapy both with and without progression of disease in advanced urothelial cancer.

George Ansstas, MD, and Firas B. Badin, MD, discuss the potential clinical implications of using circulating tumor DNA as a predictive biomarker in solid tumor patients treated with immunotherapy.

Petros Grivas, MD, PhD, presents the case of a 78-year-old man with PD-L1+ metastatic urothelial carcinoma, and the panelists share insight on their treatment approach for the given patient.

Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts.

CancerNetwork® spoke with Quita Highsmith and Monica Baskin, MD, about the Advancing Inclusive Research Alliance and efforts to include more diverse populations in clinical trials.

An oncology pharmacist speaks about the occurance of left ventricular dysfunction noted with margetuximab in the treatment of HER2-positive metastatic breast cancer.

An oncology pharmacist talks infusion-related reactions with margetuximab in the treatment of HER2-positive metastatic breast cancer.

Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.

Thomas Powles, MBBS, MRCP, MD, reviews data and results from the phase 3 JAVELIN Bladder 100 trial for patients with locally advanced or metastatic urothelial cancer.

Patients with relapsed/refractory B-cell malignancies may potentially benefit from the combination of zandelisib and zanubrutinib.

Two medical oncologists summarize data on use of circulating tumor DNA as a predictive biomarker in solid tumor patients treated with pembrolizumab.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, provide insight on how they approach the patient selection of maintenance therapy in advanced urothelial carcinoma.

Oncology pharmacist Sandra Cuellar, PharmD, BCOP, FASHP, details the unique mechanism of action of margetuximab in the treatment of HER2-positive metastatic breast cancer.

Experts review a preclinical study of the anti-HER3 monoclonal antibody seribantumab, used in cell lines and mouse models of solid tumors.

This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.

Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.

Experts in bladder cancer comment on the role of PD-L1 testing in the frontline setting for advanced urothelial cancer and its impact on the use of up-front carboplatin or immunotherapy.

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, share their approach to frontline therapy for patients with advanced urothelial carcinoma and consider the impact of cisplatin eligibility.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Neil Iyengar, MD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Vijayakrishna Gadi, MD, PhD, share clinical pearls for the evolving treatment landscape of HER+ metastatic breast cancer.